according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Mometasone / Formoterol Metered Dose Inhaler Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Pharmaceutical

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person

responsible for the SDS

: EHSSTEWARD@organon.com

1.4 Emergency telephone number

+1-215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Aerosols, Category 3 H229: Pressurised container: May burst if heated.

Long-term (chronic) aquatic hazard, Cat-

H411: Toxic to aquatic life with long lasting effects.

egory 2

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

*

Signal word : Warning

Hazard statements : H229 Pressurised container: May burst if heated.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P210 Keep away from heat, hot surfaces, sparks, open

flames and other ignition sources. No smoking.

P251 Do not pierce or burn, even after use. P273 Avoid release to the environment.

Response:

P391 Collect spillage.

Storage:

P410 + P412 Protect from sunlight. Do not expose to tem-

peratures exceeding 50 °C/ 122 °F.

Additional Labelling

Contains fluorinated greenhouse gases. (HFC-227ea)

1.8 % by mass of the contents are flammable.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

May displace oxygen and cause rapid suffocation.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Ethanol#	64-17-5	Flam. Liq. 2; H225	1.8
	200-578-6	Eye Irrit. 2; H319	
	603-002-00-5		
		specific concentration	
		limit	
		Eye Irrit. 2; H319	
		>= 50 %	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

Mometasone	83919-23-7	Repr. 1B; H360Df	>= 0.087 - <=
Womerasone	00313 20 7	STOT RE 2; H373	0.17
		(Immune system,	
		Liver, Kidney, Skin)	
		Aquatic Chronic 1; H410	
		M-Factor (Chronic	
		aquatic toxicity): 100	
Formoterol	43229-80-7	Acute Tox. 4; H332	>= 0.0009 - <=
		Carc. 2; H351 Repr. 2; H361d	0.0087
		STOT SE 1; H370	
		(Cardio-vascular	
		system, Central nervous system)	
		STOT RE 1; H372	
		(Heart)	
		Acute toxicity esti-	
		mate	
		Acute inhalation tox-	
		icity (dust/mist): 1.5 mg/l	

For explanation of abbreviations see section 16. # Voluntarily-disclosed substance

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention immediately.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Gas reduces oxygen available for breathing.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

If the temperature rises there is danger of the vessels bursting

due to the high vapor pressure.

Hazardous combustion prod: :

ucts

Fluorine compounds

Carbon oxides

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Evacuate personnel to safe areas.

Ventilate the area.

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe vapours or spray mist.

Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Keep away from heat, hot surfaces, sparks, open flames and

other ignition sources. No smoking.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep tightly closed. Keep in a cool, well-ventilated place.
 Store in accordance with the particular national regulations.
 Do not pierce or burn, even after use. Keep cool. Protect from

sunlight.

Advice on common storage : Do not store with the following product types:

Self-reactive substances and mixtures

Organic peroxides Oxidizing agents Flammable solids Pyrophoric liquids Pyrophoric solids

Self-heating substances and mixtures

Substances and mixtures, which in contact with water, emit

flammable gases Explosives

Gases

7.3 Specific end use(s)

Specific use(s) : No data available

No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Ethanol	64-17-5	OELV - 15 min (STEL)	1,000 ppm	IE OEL
Mometasone	83919-23-7	TWA	1 μg/m3 (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 μg/100 cm ²	Internal
Formoterol	43229-80-7	TWA	0.05 μg/m3 (OEB 5)	Internal

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

 |
 |
 Wipe limit
 0.5 μg/100 cm²
 Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

End Use	Exposure routes	Potential health ef-	Value
		fects	
Workers	Inhalation	Long-term systemic	61279 mg/m3
		effects	
Consumers	Inhalation	Long-term systemic	6533 mg/m3
		effects	
Workers	Inhalation	Long-term systemic	950 mg/m3
		effects	
Workers	Skin contact	Long-term systemic	343 mg/kg
		effects	bw/day
Consumers	Inhalation	Long-term systemic	114 mg/m3
		effects	
Consumers	Skin contact	Long-term systemic	206 mg/kg
		effects	bw/day
Consumers	Ingestion	Long-term systemic	87 mg/kg
		effects	bw/day
	Workers Consumers Workers Workers Consumers Consumers	Workers Inhalation Consumers Inhalation Workers Inhalation Workers Skin contact Consumers Inhalation Consumers Skin contact	Workers Inhalation Long-term systemic effects Consumers Inhalation Long-term systemic effects Workers Inhalation Long-term systemic effects Workers Skin contact Long-term systemic effects Consumers Inhalation Long-term systemic effects Consumers Skin contact Long-term systemic effects Consumers Ingestion Long-term systemic

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
1,1,1,2,3,3,3-Heptafluoropropane	Fresh water	0.1 mg/l
	Intermittent use/release	1 mg/l
	Sewage treatment plant	1.73 mg/l
	Fresh water sediment	1.3 mg/kg
Ethanol	Fresh water	0.96 mg/l
	Freshwater - intermittent	2.75 mg/l
	Marine water	0.79 mg/l
	Sewage treatment plant	580 mg/l
	Fresh water sediment	3.6 mg/kg dry
		weight (d.w.)
	Marine sediment	2.9 mg/kg dry
		weight (d.w.)
	Soil	0.63 mg/kg dry
		weight (d.w.)
	Oral (Secondary Poisoning)	380 mg/kg food

8.2 Exposure controls

Personal protective equipment

Skin and body protection : Skin should be washed after contact.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to I.S. EN 137

Filter type : Self-contained breathing apparatus

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : aerosol

Colour : white to off-white

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

-16.5 °C

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Vapour pressure : 3,900 hPa (20 °C)

Relative density : 5.9

Density : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

Relative vapour density : 5.9

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : If the temperature rises there is danger of the vessels bursting

due to the high vapor pressure.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

Version **Revision Date:** SDS Number: Date of last issue: 30.09.2023 2.21 06.04.2024 76095-00023 Date of first issue: 16.03.2015

Components:

Ethanol:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Method: OECD Test Guideline 401

: LC50 (Rat): 124.7 mg/l Acute inhalation toxicity

Exposure time: 4 h Test atmosphere: vapour

Mometasone:

Acute oral toxicity LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity LC50 (Rat): > 3.3 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute toxicity (other routes of :

administration)

LD50 (Rat): 300 mg/kg

Application Route: Subcutaneous

Symptoms: Breathing difficulties

Formoterol:

Acute oral toxicity : LD50 (Rat): 3,130 mg/kg

LD50 (Mouse): 6,700 mg/kg

Acute inhalation toxicity LC50 (Rat): 1.5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity Remarks: No data available

Acute toxicity (other routes of :

administration)

LD50 (Rat): 1,000 mg/kg

Application Route: Subcutaneous

LD50 (Mouse): 640 mg/kg

Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

Components:

Ethanol:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Mometasone:

Species : Rabbit

Result : No skin irritation

Formoterol:

Species : Rabbit

Result : No skin irritation Remarks : slight irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Ethanol:

Species : Rabbit

Method : OECD Test Guideline 405

Result : Irritation to eyes, reversing within 21 days

Mometasone:

Species : Rabbit

Result : No eye irritation

Formoterol:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Ethanol:

Test Type : Local lymph node assay (LLNA)

Exposure routes : Skin contact Species : Mouse

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

Result : negative

Mometasone:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Assessment : Does not cause skin sensitisation.

Result : negative

Remarks : The results of a test on guinea pigs showed this substance to

be a weak skin sensitiser.

Formoterol:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Result : Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:

Ethanol:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Rodent dominant lethal test (germ cell) (in vivo)

Species: Mouse

Application Route: Ingestion

Result: equivocal

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: positive

Test Type: Mouse Lymphoma

Result: negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Test Type: Chromosomal aberration

Species: Rat

Cell type: Bone marrow

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Formoterol:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosomal aberration

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Test Type: Micronucleus test

Species: Rat

Application Route: Oral Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Mometasone:

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years

Dose : 0.067 mg/kg body weight

Result : negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

Species : Mouse
Application Route : Inhalation
Exposure time : 19 Months

Dose : 0.160 mg/kg body weight

Result : negative

Formoterol:

Species : Rat
Application Route : Oral
Exposure time : 2 Years

LOAEL : 0.5 mg/kg body weight

Target Organs : Ovary

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Species : Mouse
Application Route : Oral
Exposure time : 18 month(s)

LOAEL : 2 mg/kg body weight

Target Organs : Adrenal gland, Liver, Uterus (including cervix)

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Carcinogenicity - Assess-

ment

: Limited evidence of carcinogenicity in animal studies

Reproductive toxicity

Not classified based on available information.

Components:

Ethanol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Mouse

Application Route: Ingestion

Result: negative

Mometasone:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Subcutaneous

Fertility: NOAEL: 0.015 mg/kg body weight

Symptoms: Reduced embryonic survival, Reduced foetal

weight

Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal develop-

ment

: Test Type: Embryo-foetal development

Species: Mouse

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmen-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

tal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight

Result: Effects on newborn

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

Formoterol:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL: 3 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 0.2 mg/kg body weight Result: Embryo-foetal toxicity, No malformations were ob-

served.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 3 mg/kg body weight

Result: Malformations were observed.

Test Type: Embryo-foetal development

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

Species: Rat

Application Route: inhalation (dust/mist/fume)

Developmental Toxicity: NOAEL: 1.2 mg/kg body weight

Result: No embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 60 mg/kg body weight Result: Embryo-foetal toxicity, No malformations were ob-

served.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

Components:

Mometasone:

Remarks : Based on available data, the classification criteria are not met.

Formoterol:

Exposure routes : Ingestion, inhalation (dust/mist/fume)

Target Organs : Cardio-vascular system, Central nervous system

Assessment : Causes damage to organs.

STOT - repeated exposure

Not classified based on available information.

Components:

Mometasone:

Exposure routes : inhalation (dust/mist/fume)

Target Organs : Immune system, Liver, Kidney, Skin

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Formoterol:

Exposure routes : Ingestion, inhalation (dust/mist/fume)

Target Organs : Hear

Assessment : Causes damage to organs through prolonged or repeated

exposure.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

Repeated dose toxicity

Components:

Ethanol:

Species : Rat

NOAEL : 1,280 mg/kg LOAEL : 3,156 mg/kg Application Route : Ingestion Exposure time : 90 Days

Mometasone:

Species : Rat

NOAEL : 0.005 mg/kg
LOAEL : 0.3 mg/kg
Application Route : Oral

Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog LOAEL : 0.5 mg/kg Application Route : Oral Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat

NOAEL : 0.00013 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, Liver, thymus gland

Species : Dog

NOAEL : 0.0005 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, thymus gland, Liver

Formoterol:

Species : Dog

LOAEL : >= 1.5 mg/kg
Application Route : Inhalation
Exposure time : 13 Weeks
Target Organs : Heart

Species : Rat
NOAEL : 0.14 mg/kg
Application Route : Inhalation
Exposure time : 13 Weeks

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

Target Organs : Heart

Species : Dog

LOAEL : 0.003 mg/kg

Application Route : Oral Exposure time : 1 yr Target Organs : Heart

Species : Rat
LOAEL : 0.3 mg/kg
Application Route : Oral
Exposure time : 1 yr
Target Organs : Heart

Aspiration toxicity

Not classified based on available information.

Components:

Mometasone:

Not applicable

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

Mometasone:

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper res-

piratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

Formoterol:

Inhalation : Target Organs: Heart

Symptoms: Palpitation, Tremors, Dizziness, Headache, dry

mouth, Nausea, Fatigue

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

Further information

Components:

Mometasone:

Remarks : Dermal absorption possible

SECTION 12: Ecological information

12.1 Toxicity

Components:

Ethanol:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Ceriodaphnia (water flea)): > 1,000 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

ErC50 (Chlorella vulgaris (Fresh water algae)): 275 mg/l

Exposure time: 72 h

EC10 (Chlorella vulgaris (Fresh water algae)): 11.5 mg/l

Exposure time: 72 h

Toxicity to microorganisms : EC50 (Pseudomonas putida): 6,500 mg/l

Exposure time: 16 h

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC: 9.6 mg/l Exposure time: 9 d

Species: Daphnia magna (Water flea)

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l

Exposure time: 7 d

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 5 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

: EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.00014 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0.34 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic

toxicity)

100

Formoterol:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 120 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 114 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 94 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 30

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

12.2 Persistence and degradability

Components:

Ethanol:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 84 % Exposure time: 20 d

Mometasone:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 28 d

Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)

Method: OECD Test Guideline 111

12.3 Bioaccumulative potential

Components:

Ethanol:

Partition coefficient: n-

octanol/water

log Pow: -0.35

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 107.1 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 4.68

Formoterol:

Partition coefficient: n-

octanol/water

log Pow: 0.41

12.4 Mobility in soil

Components:

Mometasone:

Monietasone.

Distribution among environmental compartments

log Koc: 4.02

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

Global warming potential

Regulation (EU) No 517/2014 on fluorinated greenhouse gases

Product:

100-year global warming potential: 3,158

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Please ensure aerosol cans are sprayed completely empty

(including propellant)

Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : UN 1950
ADR : UN 1950
RID : UN 1950
IMDG : UN 1950
IATA : UN 1950

14.2 UN proper shipping name

ADN : AEROSOLS

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

ADR : AEROSOLS

RID : AEROSOLS

IMDG : AEROSOLS

(Mometasone)

IATA : Aerosols, non-flammable

14.3 Transport hazard class(es)

Class Subsidiary risks

 ADN
 : 2
 2.2

 ADR
 : 2
 2.2

 RID
 : 2
 2.2

IMDG : 2.2 IATA : 2.2

14.4 Packing group

ADN

Packing group : Not assigned by regulation

Classification Code : 5A Labels : 2.2

ADR

Packing group : Not assigned by regulation

Classification Code : 5A Labels : 2.2 Tunnel restriction code : (E)

RID

Packing group : Not assigned by regulation

Classification Code : 5A Hazard Identification Number : 20 Labels : 2.2

IMDG

Packing group : Not assigned by regulation

Labels : 2.2 EmS Code : F-D, S-U

IATA (Cargo)

Packing instruction (cargo : 203

aircraft)

Packing instruction (LQ) Y203

Packing group : Not assigned by regulation Labels : Non-flammable, non-toxic Gas

203

IATA (Passenger)

Packing instruction (passen-

ger aircraft)

Packing instruction (LQ) : Y203

Packing group : Not assigned by regulation

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.21 06.04.2024 76095-00023 Date of first issue: 16.03.2015

Labels Non-flammable, non-toxic Gas

14.5 Environmental hazards

ADN

Environmentally hazardous yes

Environmentally hazardous yes

Environmentally hazardous yes

IMDG

Marine pollutant yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Not applicable

REACH - Restrictions on the manufacture, placing on

the market and use of certain dangerous substances,

mixtures and articles (Annex XVII)

REACH - Candidate List of Substances of Very High Not applicable

Concern for Authorisation (Article 59).

Regulation (EC) No 1005/2009 on substances that de-Not applicable

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu-Not applicable

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia-Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation Not applicable

(Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2

E2 **ENVIRONMENTAL** 200 t 500 t

HAZARDS

The components of this product are reported in the following inventories:

AICS not determined

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H225 : Highly flammable liquid and vapour. H319 : Causes serious eye irritation.

H332 : Harmful if inhaled.

H351 : Suspected of causing cancer.

H360Df : May damage the unborn child. Suspected of damaging fertili-

ty.

H361d : Suspected of damaging the unborn child.

H370 : Causes damage to organs.

H372 : Causes damage to organs through prolonged or repeated

exposure.

H373 : May cause damage to organs through prolonged or repeated

exposure if inhaled.

H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Carc. : Carcinogenicity
Eye Irrit. : Eye irritation
Flam. Liq. : Flammable liquids
Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure STOT SE : Specific target organ toxicity - single exposure

IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occu-

pational Exposure Limit Values - Code of Practice, Schedule 1

and 2

IE OEL / OELV - 15 min : Occupational exposure limit value (15-minute reference peri-

(STEL) od

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Mometasone / Formoterol Metered Dose Inhaler Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.21
 06.04.2024
 76095-00023
 Date of first issue: 16.03.2015

associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

Aerosol 3 H229 Based on product data or assessment

Aquatic Chronic 2 H411 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN